pharmaceutical communications
NHS achieves new record for cancer checks for patients
Nearly three million patients have had cancer checks by the NHS in the last year
NHS reports rise in prostate cancer treatments in England
Prostate Cancer UK’s risk checker has been used over a million times since its launch in February
NHS to roll out brain laser therapy for epilepsy patients
There are around 600,000 people living with epilepsy across the UK
How can pharma align its brand strategy with the NHS Reset?
Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era
Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home
Covid-19: how is it impacting on the NHS Long-term Plan?
Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond
AI: opportunities and barriers to improving healthcare
How AI is shaping the future of healthcare
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma